Wednesday, November 9, 2016

BIOCON APPROACHES USFDA FOR APPROVAL

Biocon and its partner Mylan have submitted an application for one of their product - biosimilar trastuzumab, to the USFDA.

Biocon says that this product is a proposed biosimilar to branded trastuzumab, which is indicated to treat certain HER2-positive breast and gastric cancers. 

No comments:

Post a Comment